Malignant effusions and immunogenic tumour-derived exosomes

[1]  Laurence Zitvogel,et al.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming , 2001, Nature Medicine.

[2]  G. Parham,et al.  In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. , 2000, American journal of obstetrics and gynecology.

[3]  Eli Gilboa,et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. , 2000, Nature Medicine.

[4]  G. Parham,et al.  Induction of Ovarian Tumor‐Specific CD8+ Cytotoxic T Lymphocytes by Acid‐Eluted Peptide‐Pulsed Autologous Dendritic Cells , 2000, Obstetrics and gynecology.

[5]  M. Kleijmeer,et al.  Follicular Dendritic Cells Carry MHC Class II-Expressing Microvesicles at Their Surface1 , 2000, The Journal of Immunology.

[6]  S. Cannistra,et al.  Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1 , 2000, The Journal of Immunology.

[7]  H. Rammensee,et al.  Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis , 2000, The Journal of experimental medicine.

[8]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[9]  K. Koda,et al.  Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes , 1999, Journal of surgical oncology.

[10]  Laurence Zitvogel,et al.  Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.

[11]  M. Grégoire,et al.  Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. , 1999, Cancer research.

[12]  H. Ragde,et al.  Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment , 1999, The Prostate.

[13]  M. Hanna,et al.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[14]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[15]  Laurence Zitvogel,et al.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.

[16]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[17]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[18]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[19]  D. Elias,et al.  T‐cell receptor CDR3 size distribution analysis to evaluate specific T‐cell response to cancer vaccines , 1997, International journal of cancer.

[20]  P. Srivastava,et al.  Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. , 1997, Methods.

[21]  G. Carcelain,et al.  Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. , 1997, Journal of immunology.

[22]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[23]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[24]  E. Atkinson,et al.  Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[25]  T. Eberlein,et al.  TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. , 1994, Journal of immunology.

[26]  T. Eberlein,et al.  T cell receptor Vβ2 and Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer , 1993 .

[27]  T. Eberlein,et al.  T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. , 1993, Journal of immunology.

[28]  Kenichi Tanaka,et al.  Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. , 1991, Cancer research.

[29]  W. Urba,et al.  Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Boon,et al.  Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis , 1983, The Journal of experimental medicine.